The Green Divide: Cannabis, Sport, and the Gap Between Legalisation and Reality

There is a particular cruelty in a medicine that exists but cannot be reached. A locked door behind glass, visible to the desperate, inaccessible by design. In the United Kingdom, medical cannabis has been legal since November 2018, a landmark shift born from the tireless campaigning of mothers like Hannah Deacon and other parents who watched their children suffer catastrophic epileptic seizures while a proven treatment sat behind bureaucratic red tape. Seven years on, the law says one thing and the system says another. Most patients who need medical cannabis cannot access it through the NHS. They go private. They pay hundreds of pounds per month. They choose between their health and their household budgets.

This is a story about access, about the chasm between what a society legislates and what it delivers. And it is, perhaps unexpectedly, a story that runs through the very heart of professional sport.

When the Rules Changed — For Some

In sport, the cannabis conversation has shifted dramatically over the past decade. The turning point, etched into collective memory, arrived at the 2021 Tokyo Olympics. Sha'Carri Richardson, the blazing American sprinter who had just won the 100 metres at the US Trials in 10.86 seconds, tested positive for THC. She had used cannabis to cope with the death of her biological mother. The United States Anti-Doping Agency handed her a one-month ban. She missed the Olympic final.

The backlash was seismic. Athletes, commentators, and the public questioned why a substance now legal in most US states could derail a career on the world's biggest stage. Richardson became a symbol not of failure but of absurdity — a system punishing an individual for a substance that millions use openly, legally, without stigma.

That moment cracked something open. It forced sport's governing bodies to confront a question they had long avoided: what exactly are anti-doping cannabis rules protecting?

The Quiet Revolution in American Leagues

The answer, it turned out, was "less than we thought."

The NFL led the shift. In the 2020 Collective Bargaining Agreement, the league effectively stopped suspending players for cannabis use. Testing windows were narrowed. Thresholds were raised. The message was clear: marijuana use, in a sport where men collide at high velocity and manage chronic pain daily, was no longer worth the punitive theatre.

The NBA followed. Commissioner Adam Silver had signalled openness for years, and by 2023, the league removed cannabis from its anti-drug testing programme entirely. Players were no longer screened for THC. The league that had banned players for an entire season in the 1980s for marijuana use quietly conceded the war.

The UFC went further. Under the guidance of USADA, the promotion stopped testing fighters for marijuana out of competition in 2021, acknowledging that THC does not enhance athletic performance. Fighters openly spoke about using CBD for recovery, inflammation, and sleep.

"We were punishing people for something that had nothing to do with cheating. That's not what anti-doping is supposed to be." — Travis Tygart, USADA CEO

The British Paradox

Here is where the UK medical cannabis story and the sports world collide in uncomfortable ways. Professional athletes in major American leagues now operate in environments where cannabis is tolerated, destigmatised, and in some cases actively promoted through CBD endorsement deals. Companies like cbdMD and Charlotte's Web have partnered with athletes, positioning CBD as a recovery tool. The global CBD sports market was valued at approximately $2.8 billion in 2023, with projections suggesting it could reach $6 billion by 2028.

Meanwhile, in the United Kingdom, a child with treatment-resistant epilepsy may wait months for a specialist willing to prescribe medical cannabis — if they can find one at all. Since legalisation in 2018, NHS prescriptions for unlicensed cannabis-based products have remained vanishingly rare. A 2022 report by the Centre for Medicinal Cannabis found that fewer than five NHS prescriptions had been issued for unlicensed medical cannabis products in the first three years after the law changed. The private market, by contrast, served an estimated 25,000 to 30,000 patients, most paying between £150 and £400 per month out of pocket.

The disparity is staggering. An NFL linebacker can consume THC recreationally without consequence. A British parent with a severely epileptic child must navigate a labyrinth of specialist referrals, clinical commissioning guidelines, and institutional scepticism to access the same plant in pharmaceutical form.

Pain, Performance, and the Double Standard

The question at the centre of this tension is not really about cannabis. It is about who gets to decide what constitutes legitimate medicine, and who gets to access it.

Professional athletes occupy a peculiar space. They are simultaneously the most scrutinised bodies in society and the most marketable. When an NBA star endorses a CBD recovery balm, it carries the implicit message that this substance is safe, effective, and modern. When that same substance is denied to a patient in Manchester because their GP has never been trained in cannabinoid medicine, the message is different: this is experimental, risky, unproven.

Both cannot be true.

The science has not changed depending on which side of the Atlantic you stand. Epidiolex, a CBD-based epilepsy drug, received FDA approval in 2018 and MHRA approval shortly after. It works. It reduces seizures. It saves lives. Yet access to broader cannabis-based medicines in the UK remains bottlenecked by a medical establishment that, by and large, was never taught about the endocannabinoid system during training and remains structurally reluctant to prescribe.

What Athletes Know That Systems Do Not

There is a directness in the athlete's relationship with the body that institutional medicine often lacks. Professional sport has, for all its faults, learned to listen to what works. When NBA players reported that CBD helped with sleep and inflammation, the league did not commission a decade of studies before adjusting policy. When UFC fighters said marijuana was not performance-enhancing, USADA agreed and removed it from the testing panel. The pragmatism was refreshing.

Contrast this with the UK's approach to medical cannabis, where the NICE guidelines remain cautious, the British Paediatric Neurology Association has issued restrictive guidance, and consultants face personal liability concerns when prescribing unlicensed products. The system protects itself. The patient waits.

Two mothers fought British bureaucracy to obtain lifesaving cannabis medicines for their children. They succeeded in changing the law. But changing the law and changing access are, as it turns out, profoundly different victories.

The Road Ahead

For sport, the trajectory is clear. Cannabis restrictions will continue to soften. The World Anti-Doping Agency still lists THC as a prohibited substance in competition, but its presence on the list is under increasing scrutiny. The 2024 WADA Prohibited List review process included public commentary on cannabinoids for the first time. The direction of travel points toward eventual removal, or at minimum, a significant threshold increase.

For patients in the UK, the path is less certain. Private clinics are proliferating, and patient numbers are growing, but the NHS remains largely closed off. Advocacy groups like End Our Pain and Sapphire Medical Clinics continue to push for systemic change, but progress is measured in years, not months.

The disconnect between these two worlds — sport and medicine, elite bodies and vulnerable ones — reveals something uncomfortable about how societies distribute care. A substance is dangerous when a poor patient needs it. It is innovative when a wealthy athlete endorses it. It is criminal when consumed on a council estate. It is "wellness" when consumed in a locker room.

Sport did not create this paradox. But by moving faster than the medical establishment, by listening to its athletes and adjusting its rules with relative speed, professional sport has inadvertently exposed how slowly the machinery of public health can move when the patients are not millionaires.

That is the real story. Not a policy debate. A moral one. And it is far from over.